Paper6352005
A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.
Løber J and 5 others. Cancer, 1983. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Papers, record 6352005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6352005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Breast Neoplasms | Major topic |
| Chlorambucil | Major topic |
| Prednimustine | Major topic |
| Adult | |
| Aged | |
| Clinical Trials as Topic | |
| Drug Therapy, Combination | |
| Female | |
| Hallucinations | |
| Hematologic Diseases | |
| Humans | |
| Middle Aged | |
| Nausea | |
| Prednisolone | |
| Random Allocation |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8164452 | Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma. | Med Oncol Tumor Pharmacother | 1993 | https://conductscience.org/library/papers/8164452 | PubMed |
| 6871484 | Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study. | Breast Cancer Res Treat | 1983 | https://conductscience.org/library/papers/6871484 | PubMed |
| 3948307 | Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3948307 | PubMed |
| 3568275 | Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3568275 | PubMed |
| 3170130 | Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. | Invest New Drugs | 1988 | https://conductscience.org/library/papers/3170130 | PubMed |
| 2924378 | Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2924378 | PubMed |
| 2491962 | Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2491962 | PubMed |
| 2013118 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/2013118 | PubMed |
| 1914086 | Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/1914086 | PubMed |
| 1537076 | Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. | Cancer Chemother Pharmacol | 1992 | https://conductscience.org/library/papers/1537076 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6352005
GET https://conductscience.org/api/papers/v1/6352005/authors